[{"id":"131edcdb-27c4-4090-85ed-cdfe17502f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743766","created_at":"2021-01-18T18:20:12.816Z","updated_at":"2025-02-25T14:27:49.581Z","phase":"Phase 2","brief_title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","source_id_and_acronym":"NCT03743766","lead_sponsor":"John Kirkwood","biomarkers":" PD-1 • LAG3","pipe":" | ","alterations":" PD-1 expression • LAG3 expression","tags":["PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/29/2019","start_date":" 03/29/2019","primary_txt":" Primary completion: 07/03/2024","primary_completion_date":" 07/03/2024","study_txt":" Completion: 07/03/2024","study_completion_date":" 07/03/2024","last_update_posted":"2024-09-25"},{"id":"c39317e9-2ffe-4fe5-b487-781ec7511b8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923180","created_at":"2021-01-18T14:21:11.868Z","updated_at":"2024-07-02T16:34:25.763Z","phase":"Phase 2","brief_title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","source_id_and_acronym":"NCT02923180","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression","tags":["AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"},{"id":"699fb00b-0053-4189-8bc1-8cdb7804cacf","acronym":"IMAGINE","url":"https://clinicaltrials.gov/study/NCT04062656","created_at":"2021-01-18T19:54:32.894Z","updated_at":"2024-07-02T16:35:15.444Z","phase":"Phase 2","brief_title":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","source_id_and_acronym":"NCT04062656 - IMAGINE","lead_sponsor":"University Hospital, Essen","biomarkers":" LAG3","pipe":" | ","alterations":" LAG3 expression","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-11"},{"id":"59cf1c76-20c0-482d-a704-e18624a0a2cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787613","created_at":"2023-03-28T14:05:08.783Z","updated_at":"2024-07-02T16:35:18.055Z","phase":"Phase 2","brief_title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","source_id_and_acronym":"NCT05787613","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • ROS1 • LAG3","pipe":" | ","alterations":" PD-L1 expression • ROS1 rearrangement • LAG3 expression","tags":["PD-L1 • ROS1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ROS1 rearrangement • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-02-22"},{"id":"69e8cde1-45a2-4c9d-a141-58ffae97e9df","acronym":"","url":"https://clinicaltrials.gov/study/NCT06259162","created_at":"2024-02-14T15:26:22.557Z","updated_at":"2024-07-02T16:35:19.439Z","phase":"","brief_title":"LAG3 Expression in Triple Negative Breast Cancer","source_id_and_acronym":"NCT06259162","lead_sponsor":"Samsung Medical Center","biomarkers":" LAG3","pipe":" | ","alterations":" LAG3 expression","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-02-14"},{"id":"fd66e2fe-fd06-45f6-9687-e9f105e1a997","acronym":"","url":"https://clinicaltrials.gov/study/NCT04326257","created_at":"2021-01-18T20:57:23.420Z","updated_at":"2025-02-25T14:29:11.740Z","phase":"Phase 2","brief_title":"Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy","source_id_and_acronym":"NCT04326257","lead_sponsor":"Dan Zandberg","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" LAG3 expression • CTLA4 expression","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 08/12/2023","primary_completion_date":" 08/12/2023","study_txt":" Completion: 08/12/2024","study_completion_date":" 08/12/2024","last_update_posted":"2024-02-07"},{"id":"db068b7e-0c84-41a8-8c88-e6838f8d4682","acronym":"","url":"https://clinicaltrials.gov/study/NCT03219268","created_at":"2021-01-17T17:21:23.536Z","updated_at":"2024-07-02T16:35:25.591Z","phase":"Phase 1","brief_title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","source_id_and_acronym":"NCT03219268","lead_sponsor":"MacroGenics","biomarkers":" PD-L1 • PD-1 • LAG3","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression","tags":["PD-L1 • PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Margenza (margetuximab-cmkb) • tebotelimab (MGD013)"],"overall_status":"Completed","enrollment":" Enrollment 277","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 02/08/2023","primary_completion_date":" 02/08/2023","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2023-12-21"},{"id":"35641ab2-6f4d-40e3-8334-a2f46e81a6fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020912","created_at":"2021-08-25T14:53:19.986Z","updated_at":"2024-07-02T16:35:29.739Z","phase":"Phase 2","brief_title":"Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy","source_id_and_acronym":"NCT05020912","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3","pipe":" | ","alterations":" LAG3 expression","tags":["PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-11-09"},{"id":"1418a6c5-fd7e-4f45-9af7-c21d6ef0bb58","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566978","created_at":"2021-01-18T21:48:55.475Z","updated_at":"2024-07-02T16:35:33.079Z","phase":"Phase 1","brief_title":"89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04566978","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" LAG3","pipe":" | ","alterations":" LAG3 expression","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fianlimab (REGN3767)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 09/11/2020","start_date":" 09/11/2020","primary_txt":" Primary completion: 09/11/2025","primary_completion_date":" 09/11/2025","study_txt":" Completion: 09/11/2025","study_completion_date":" 09/11/2025","last_update_posted":"2023-10-17"},{"id":"53d79e9d-a4a5-4744-ac61-e6efb07bd6bc","acronym":"MIMOSA","url":"https://clinicaltrials.gov/study/NCT04368468","created_at":"2021-01-18T21:06:05.068Z","updated_at":"2024-07-02T16:35:58.565Z","phase":"","brief_title":"Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC","source_id_and_acronym":"NCT04368468 - MIMOSA","lead_sponsor":"Institut Claudius Regaud","biomarkers":" PD-L1 • LAG3 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • LAG3 expression • HAVCR2 expression","tags":["PD-L1 • LAG3 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • LAG3 expression • HAVCR2 expression"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 01/31/2021","study_completion_date":" 01/31/2021","last_update_posted":"2022-12-23"},{"id":"2b3fa159-be2b-4e28-bb38-c285816a337b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05346276","created_at":"2022-04-26T15:01:51.935Z","updated_at":"2024-07-02T16:36:10.560Z","phase":"","brief_title":"PET Imaging of LAG-3 Expression","source_id_and_acronym":"NCT05346276","lead_sponsor":"The First Affiliated Hospital of Xiamen University","biomarkers":" LAG3","pipe":" | ","alterations":" LAG3 expression","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/06/2022","start_date":" 04/06/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-05-12"}]